Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review

Isabelle Claire Lutz,1 Karel Allegaert,2,3 Jan N de Hoon,4 Heleen Marynissen

ABSTRACT

Background Neonatal hypoxic ischaemic encephalopathy due to perinatal asphyxia, can result in severe neurodevelopmental disability or mortality. Hypothermia is present the only proven neuroprotective intervention. During hypothermia, the neonate may need a variety of drugs with their specific pharmacokinetic profile. The aim of this paper is to determine the effect that hypothermia for neonates suffering from hypoxic ischaemic encephalopathy has on the pharmacokinetics and to what extent dosing regimens need adjustments.

Method A systematic search was performed on PubMed, Embase and Cochrane Library of literature (2000–2020) using a combination of the following search terms: therapeutic hypothermia, neonate, hypoxic ischemic encephalopathy and pharmacokinetics. Titles and abstracts were screened, and inclusion/exclusion criteria were applied. Finally, relevant full texts were read, and secondary inclusion was applied on the identified articles.

Results A total of 380 articles were retrieved, and 34 articles included after application of inclusion/exclusion criteria and duplicate removal, two additional papers were included as suggested by the reviewers. Twelve out of 36 studies on 15 compounds demonstrated a significant decrease in clearance, be it that the extent differs between routes of elimination and compounds, but most pronounced for renal elimination (phenobarbital no difference, midazolam metabolite −21%, lidocaine −24%; morphine −21% to −47%, gentamicin −25% to −35%, amikacin −40%) during hypothermia. The data as retrieved in literature were subsequent compared with the dosing regimen as stated in the Dutch paediatric formulary.

Conclusion Depending on the drug-specific disposition characteristics, therapeutic hypothermia in neonates with hypoxic ischaemic encephalopathy affects pharmacokinetics.

INTRODUCTION

Neonatal hypoxic ischaemic encephalopathy (HIE), brain damage sustained as a result of perinatal asphyxia, occurs in 1.5 out of 1000 births1 and can result in severe neurodevelopmental disability or mortality in respectively 24.9% and 34.1% of cases.2 Perinatal asphyxia is a condition characterised by a persistently low Apgar score (≤5) assessed at 5 and 10 min after birth, or metabolic acidosis, defined as a pH of <7.0 and/or base deficit of ≥16 mmol/L, measured in the fetal umbilical artery or arterial blood within 1 hour after birth.3 4 The HIE severity can be categorised by the Sarnat score into mild, moderate and severe brain injury based on the abnormality of level of consciousness, spontaneous activity, posture, tone, primitive reflexes and autonomic function.5 Alternatively, the Thompson score is another scoring system that uses similar criteria like Sarnat but also includes the presence of seizures and fontanelle tension; both scores can be used for prognosis and provide prognostic value and quantify HIE into mild, moderate and severe.6
Therapeutic hypothermia (TH) is at present the only proven effective intervention for moderate and severe HIE. It significantly reduces the mortality by 8.8% and severe morbidity by 15.4% (relative risk=0.75; number needed to treat=7). In its current approach, TH aims to cool the body temperature of the neonate to 33.5°C for the duration of 72 hours within 6 hours after birth, and a subsequently gradual rewarming at a rate of 0.3°C–0.5°C per hour. According to the current guidelines all (near)-term neonates who meet the criteria for perinatal asphyxia and are classified as moderate or severe HIE by the Thompson score should receive this treatment. 

During the hypothermic period the neonate may need a variety of different drugs ranging from antiepileptic drugs to sedatives or antibiotics. Simultaneously, different substances with different mechanisms involved are investigated on their additive neuroprotective effect. We refer the interested reader to a recent review on the pharmacodynamics of these claimed neuroprotective compounds.

However, for any drug administered to these patients, the pharmacokinetic (PK) profile may be altered by the physical state of the neonate with HIE and TH. This is due to the altered pathophysiology explained by both the disease (asphyxia) and the intervention (TH), and includes renal impairment, altered haemodynamics like cardiac output and blood flow, or altered hepatic function. The aim of this paper is to provide an overview on the effects of TH in neonates suffering from HIE have on the PK of drugs administered during this hypothermic period, and whether dosing regimens need to be adjusted.

METHODS

A systematic search was performed on PubMed, Embase and Cochrane Library of all literature between 1 January 2000 and 1 January 2020. A combination of the following search terms was hereby used: ‘therapeutic hypothermia, neonate, hypoxic ischemic encephalopathy and pharmacokinetics’. In PubMed the corresponding MeSH terms for these search terms were used. An overview of the performed search and the subsequent results is provided in figure 1.

Only articles with full-text availability written in English were included. Another inclusion criterion was the reporting of a PK parameter for at least one of the following processes: absorption, distribution, metabolism or excretion. Only studies that concerned the human species were included. Reviews and study protocols that provided no new information were excluded after screening references for secondary inclusion. Articles were excluded if the study population did not include term neonates or if TH was not applied.

First the titles of all articles were screened. If the relevance was unsure, the abstract was subsequently read. Finally, the resulting selected articles were thoroughly studied, and the references screened for secondary inclusion.

Patient and public involvement

This research was conducted without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient-relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

RESULTS

A schematic overview of the entire data selection process can be found in figure 2. By using the above-mentioned search terms, a total of 380 publications were identified for screening, secondary inclusion included. The exact number of studies for each of the performed searches can be found in figure 1. After application of the inclusion and exclusion criteria and removal of duplicates, the remaining 34 articles were deemed eligible for inclusion. To keep the overview updated, two additional papers (2-aminobiotin, lidocaine) that were not in the initial search strategy, but were suggested by the reviewers, were added in the revised version of the paper (both very recent publications, not in the initial search).

Characteristics of all retained (n=36) articles are provided in table 1. Most of the studies were prospective multicentre observational studies. The drugs reviewed ranged from those that are the current standard treatment for the occurrence of neonatal seizures (ie, phenobarbital), to various substances that have been hypothesised to have a neuroprotective effect in newborns suffering from HIE. Some PK parameters were much more frequently analysed than others. Total body clearance (C_l) was calculated in all but one of the articles, whereas absorption was only relevant in three analyses as most of the drugs are administered by intravenous route. Only 10 out of 36 articles included a normothermic control group in the study design. More common, the quantification of the effect of TH on PK was based on data pooling or literature data, and subsequent use of population PK modelling approaches.
In an attempt to facilitate comparison of the PK parameters for absorption, distribution, metabolism and excretion described in the selected articles, the quantification of these parameters can be found in Table 2a–f. Because of the different characteristics of each drug administered during the hypothermic period, the included studies as presented in Table 2a–f were sorted by drug to facilitate comparison. In the subsequent synthesis, the effect of TH on each of the PK parameters will be discussed, illustrated by available findings for different drugs.

**Absorption**

The rate and amount of absorption of a drug determines the maximum plasma concentration (Cmax) and time needed to reach this peak concentration (tmax). Absorption can best be assessed by bioavailability, which can be calculated based on the area under the curve after oral (AUCO) versus intravenous (AUCIV) administration, using the following formula: AUCO/AUCIV × 100%. There are many factors that influence absorption after oral administration such as gastric emptying, food and physicochemical characteristics of the drug. These factors can be different in neonates when compared with adults, so that for example, differences in gastric emptying rate will affect the tmax for drugs that are mainly absorbed in the duodenum. However, absorption parameters are less relevant in the context of TH as all drugs except for topiramate and melatonin are administered intravenously, where a bioavailability of 100% can be assumed.

**Topiramate**

Topiramate has been hypothesised to improve the neuroprotective effect of TH, with glutamate receptor inhibition as underlying claimed mechanism. In adults, it has a high oral bioavailability (≥80%). As topiramate is usually not used in children younger than 2 years, there were no available PK data in neonates. In all three articles, the first dose of topiramate was 5 mg/kg and was administered via nasogastric tube. The two more recent studies went on to decrease the dose to 3 mg/kg for days 2–5, whereas Filippi et al. continued with 5 mg/kg for 3 days (Table 2a). Both dosing regimens resulted in...
### Table 2a  Topiramate and melatonin

| Topiramate | n   | Study type | Absorption | $V_D$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) | Melatonin |
|------------|-----|------------|------------|--------------|-------------------------------|-----------------|-----------|
| Filippi et al\(^{14}\) | 13  | Prospective | AUC=343.2 mg/L/hour | /             | /                             | /               |           |
| Nuñez-Ramiro et al\(^{16}\) | 106 | Prospective (RCT) | AUC=77.8 mg/L/hour | /             | /                             | 19.7            | 54.1      |
| Marques et al\(^{17}\) | 52  | Prospective (RCT) | /             | 0.976        | /                             | Th=12.6         |            |

Melatonin

| Baldüini et al\(^{21}\) (Melatonin) | 5   | Prospective | AUC$_{ss}$=9.71 μg/mL/hour $t_{abs}$=2.8 hours | 1.8           | /                             | 46.0            | 26.4      |

### Table 2b  Phenobarbital

| Phenobarbital | n   | Study type | Absorption | $V_D$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) | Phenobarbital |
|---------------|-----|------------|------------|--------------|-------------------------------|-------------------|-----------------|---------------|
| van den Broek et al\(^{35}\) | 31  | Prospective | /          | 0.986        | /                             | 4.914             | 140             |
| Shellhaas et al\(^{37}\) | 39  | Retrospective | /          | 0.92         | /                             | 7.6               | 85              |
| Filippi et al\(^{38}\) | 19  | Prospective | /          | 1.56         | /                             | 6.38              | 173.3          |
| Favié et al\(^{34}\) | 113 | Prospective | /          | 1.03         | /                             | 2.394             | 298            |
| Pokorná et al\(^{36}\) | 40  | Prospective | /          | 0.519        | /                             | 2.1               | 120            |
| Šíma et al\(^{39}\) | 37  | Prospective | /          | 0.48         | /                             | 3.4               | 93.7           |

### Table 2c  Midazolam and lidocaine

| Midazolam | n   | Study type | Absorption | $V_D$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) | Midazolam |
|-----------|-----|------------|------------|--------------|-------------------------------|-------------------|-----------------|------------|
| Welzing et al\(^{40}\) | 9   | Prospective | /          | 5.91 L (median weight not calculated) | /                 | 154.0            | 7.0           |
| van den Broek et al\(^{41}\) | 53  | Prospective | /          | 1.93         | OHM=0.7 HMG 0.02              | 268.0             | 5.0            |
| Favié et al\(^{34}\) | 118 | Prospective | /          | 1.55         | OHM=0.969 $\downarrow$25.7\%=$\downarrow$8.6\%/ºC HMG=0.055 | 100              | /               |
| Lidocaine |
| Favié et al\(^{43}\) | 159 | Mixed      | /          | 2.66         | MEGX=431                      | 506              | $\downarrow$21.8\%=$\downarrow$7.3\%/ºC | /
| van den Broek et al\(^{42}\) | 48  | Mixed      | /          | 3.11         | MEGX=166                      | 397.0            | $\downarrow$24.0\%=$\downarrow$8.0\%/ºC | 5.5 |

### Table 2d  Morphine

| Morphine | n   | Study type | Absorption | $V_D$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) | Morphine |
|----------|-----|------------|------------|--------------|-------------------------------|-------------------|-----------------|----------|
| Favié et al\(^{45}\) | 244 | Prospective | /          | 2.54         | M3G=0.130 M6G=0.494 $\downarrow$14.7\%=$\downarrow$4.91\%/ºC | 259.0             | $\downarrow$20.7\%=$\downarrow$6.89\%/ºC | /
| Róka et al\(^{44}\) | 16  | Observational | /          | /             | /                             | /                 | ‘could not be calculated’ |
| Frymoyer et al\(^{23}\) | 20  | Prospective | /          | 2.286        | M3G=0.188 M6G=0.197 $\downarrow$37.0\%=$\downarrow$12.3\%/ºC | 216.0             | $\downarrow$46.7\%=$\downarrow$15.6\%/ºC | /

Continued
### Table 2e Antibiotics

| Gentamicin | n | Study type | Absorption | $V_d$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) |
|------------|---|------------|------------|--------------|-----------------------------|------------------|----------------|
| Bijleveld et al<sup>49</sup> | 47 | Prospective | / | 0.897 | / | 60 (day 2) 77.4 (29%↑ day 5) | / |
| Liu et al<sup>46</sup> | 55 | Prospective | / | / | / | / | / |
| Frymoyer et al<sup>50</sup> | 29 | Retrospective | / | 0.47 | / | 36.0 | / |
| Ting et al<sup>47</sup> | 46 | Retrospective | / | NT=0.45 HT=0.41 | / | NT=51.0 TH=33.0 | NT=7.0 HT=9.6 |
| Mark et al<sup>48</sup> | 23 | Retrospective | / | / | / | NT=50.0 HT=40.0 | NT=6.6 HT=9.2 |
| Frymoyer et al<sup>51</sup> | 52 | Retrospective | / | / | / | 17.0 | / |
| Cies et al<sup>77</sup> | 12 | Prospective | / | 0.87 | / | 132.0 | / |
| Martinkova et al<sup>78</sup> | 35 | Prospective | / | 0.40 | / | 46.0 | / |

### Other antibiotics

| Cies et al<sup>73</sup> (Ampicilline) | 13 | Prospective | / | 0.52 | / | 25.8 | / |
| Bijleveld et al<sup>53</sup> (Amoxicillin) | 125 | Prospective | / | 0.34 ($V_c$) | / | PNA 0–4=90.0 PNA 5=14.0 | 55%↑ |
| Bijleveld et al<sup>52</sup> (Benzylpenicillin) | 41 | Prospective | / | 0.62 ($V_c$) | / | PNA 0–4=160.0 PNA 5=250.0 | 56%↑ |
| Cristea et al<sup>84</sup> (Amikacin) | 56 | Retrospective | / | 0.832 | / | 49.5 | 40.6%=13.5%/°C |

### Table 2f Erythropoietin, darbepoetin, bumetanide

| Erythropoietin | n | Study type | Absorption | $V_d$ (L/kg) | Metabolite $C_L$ (mL/kg/hour) | $C_L$ (mL/kg/hour) | $t_{1/2}$ (hour) |
|----------------|---|------------|------------|--------------|-----------------------------|------------------|----------------|
| Frymoyer et al<sup>79</sup> | 47 | Prospective | / | $V_c$=0.074 $V_p$=0.096 | / | 8.3 | / |
| Wu et al<sup>68</sup> | 24 | Prospective | / | 0.095–0.178 | / | 7.7–15.6 $C_L$ ↓ with dose↑ | / |
| Roberts et al<sup>73</sup> | 26 | Prospective | / | 0.511 | / | 15.0 | 23.6 |
| Baserga et al<sup>72</sup> | 30 | Prospective | / | / | / | 40.0–50.0 | 24–35 |

### Miscellaneous

| Jullien et al<sup>81</sup> (Bumetanide) | 14 | Prospective | / | 0.23 | / | 19.8 | 8.4 |
| Pressler et al<sup>82</sup> (Bumetanide) | 14 | Prospective | / | 0.23 | / | 19.8 | 8.4 |
| Favié et al<sup>74</sup> (2-iminobiotin) | 12 | Prospective | / | $V_c$=0.138 $V_p$=0.368 | / | 113.8 | 2.9 |

AUC, area under the curve; $C_L$, total body clearance; DH, deep hypothermia; HMG, 1-hydroxymidazolam glucuronide; MEGX, monomethylglycine/xylidide; MH, moderate hypothermia; NT, normothermia; OHM, 1-hydroxymidazolam; PNA, postnatal age; RCT, randomised controlled trial; $t_{1/2}$, half life; TH, therapeutic hypothermia; $V_c$, central distribution volume; $V_p$, peripheral distribution volume.

---

a steady state within the therapeutic range of 5–20 mg/L, but steady state was only reached after 48 hours. Filippi et al<sup>81</sup> made a distinction between mild hypothermia (33°C–34°C) and deep hypothermia (30°C–33°C) to assess if the depth of hypothermia had an impact on PK. Although no significant differences were found between the observed plasma concentrations and the calculated parameters, a lower $C_{avg}$ and steady state plasma concentration ($C_{ss}$), and a longer elimination half life ($t_{1/2}$) were observed in the deep hypothermia group.
Due to the small sample size the differences were not statistically significant, however, it is possible that these effects would become statistically significant in a larger study population.16 Nuñez-Ramíro et al16 and17 Marques et al17 both used the same dosing strategy, but only the first research group calculated the AUC0–24, which was considerably lower than the one calculated by Filippi et al21 (see table 2a). Both groups concluded that a 5 mg/kg loading dose (LD) and a 3 mg/kg as a maintenance dose (MD) were too low and the time needed to reach therapeutic concentrations too long.16 18 Since there is a strong correlation between serum level and seizure control or neuroprotective effects, it is desirable to reach therapeutic concentrations too long.16 18 Since there is a strong correlation between serum level and seizure control or neuroprotective effects, it is desirable to reach therapeutic concentrations more quickly. The PK modelling suggests that an LD of 15 mg/kg followed by an MD of 5 mg/kg would lead to 90% of patients reaching therapeutic concentrations after 24 hours.14 16 offenders.14 16 Though the AUC was calculated in two of three studies, this parameter does depend on absorption, and is affected by subsequent distribution, metabolism and elimination. Unfortunately, in the absence of intravenous PK data in neonates, quantification of bioavailability and the impact of asphyxia and TH cannot be assessed.

**Melatonin**

The hormone melatonin, which regulates circadian rhythm, is produced by the pineal gland. In several animal models of HIE it has been shown to augment the neuroprotective efficacy of hypothermia by inhibiting apoptosis, stimulating antioxidant enzymes and by modulating the inflammatory response.18–20 Balduini et al21 are the first to have conducted a study with melatonin in human neonates with only five infants included, in order to study the PK (table 2a). The authors administered melatonin by continuous drip over nasogastric/orogastric tube at 0.5 µg/kg over 4 hours, after which the absorption time was estimated to be 2.8 hours.21 Larger clinical studies to evaluate the efficacy of melatonin in neonates with HIE are therefore needed.

**Distribution**

Distribution is typically expressed as volume of distribution (Vd) which represents a virtual space that the drug has dissolved in. Vd depends on substance characteristics and patient factors which can be different between neonates and adults. For example, neonates have a proportional higher body water content which can imply that the Vd per kg is higher for water-soluble compounds.22

Out of the 36 articles included in this analysis, 30 reported on aspects of the Vd, sometimes based on a central (Vc) and peripheral (Vp) distribution volume. However, only 2/30 articles described a significant impact of the TH on distribution. Interestingly, Frymoyer et al describe a 37% decrease in the Vd of morphine (8.0L in TH vs 12.7L for normothermia for an infant with mean birth weight of 3.5 kg), whereas Cies et al, on the other hand, found a 30% increase of Vd for ampicillin.22 23 Both studies compared their own data to earlier reported studies in literature, instead of a data set of normothermic controls integrated in the same analysis.25 26

---

**Table 3 Dosing recommendations of drugs used in newborns with hypoxic ischaemic encephalopathy undergoing hypothermia as provided at the Dutch paediatric formulary are compared with some recommendations reported in literature**

| Drug       | Recommendations as published | Dutch paediatric formulary |
|------------|------------------------------|---------------------------|
|            | LD (mg/kg)                  | MD (mg/kg)                |
| Phenobarbital | 20–40                        | /                         |
|            | 20–40                        | 2.5–5 in 1–2 doses/day    |
| Morphine   | 50 µg/kg                     | 5 µg/kg/hour              |
|            | 50–100 µg/kg over 60 min     | 3–20 µg/kg/hour           |
| Midazolam  | 0.05–0.1 mg/kg               | 0.05–0.1 mg/kg/hour       |
|            | 0.05 mg/kg                   | 0.05–0.1 mg/kg/hour       |
|            | 0.05 mg/kg/hour              | 0.05–0.1 mg/kg/hour       |
| Lidocaine  | >2.0–2.5 kg:2 mg/kg (10 min) | 6 mg/kg/hour (3.5 hours) →|
|            | <2.5–4.5 kg:2 mg/kg (10 min)| 3 mg/kg/hour (12 hours) →|
|            | 2 mg/kg (10 min)            | 4 mg/kg/hour (6 hours) →   |
| Topiramate | 15 mg/kg                     | Not yet validated         |
|            | 5 mg/kg/day                  | Not yet validated         |
| Erythropoietin | /                    | 1.000 U/kg every 24 hours (3x)|
|            | then every 48 hours (2x)     | Not yet validated         |
| Darbepoetin| /                            | Not yet validated         |
| Gentamicin | /                            | Not yet validated         |
| Amikacin   | /                            | Not yet validated         |

LD, loading dose; MD, maintenance dose.
Clearance: metabolisation and excretion
After absorption and distribution, drugs are slowly cleared from the body by one of three ways: (1) excretion, unchanged by the kidneys, (2) elimination via other excretion routes such as bile, sweat, saliva or milk glands, and/or (3) metabolism mainly by the liver into metabolite(s) that can be both an inactive substance or a more active molecule compared with the mother compound. Such metabolites commonly subsequently undergo additional metabolism or are eliminated by renal or other excretion routes. Quantitatively, the largest group of metabolising enzymes is the cytochrome P450 (CYP450) mono-oxygenase family. Tortorici et al.27 established that hypothermia impacted hepatic drug elimination by decreasing the activity of the CYP450 system, based on studies in brain-injured adults and healthy volunteers. However, such findings need to be integrated with isoenzyme-specific ontogeny in neonates.12 The sum of excretion in the urine of both the intact substance and metabolites that have been produced by the liver, further metabolism and excretion into bile, sweat, saliva or milk make up the C12.

If, for example, a substance is primarily cleared by excretion in the urine, renal function is the principal determinant of clearance. The Cochrane systematic review on TH could not observe any significant differences in urine output in neonates who underwent TH compared with those who did not. Furthermore, meta-analysis showed that TH did not cause a significant difference in the occurrence of acute kidney injury.2 This suggests that asphyxia, and not the intervention, is the major determinant of altered renal elimination clearance. In the first week after birth there is maturation in renal function, the rate of which depends on the gestational age (GA) at birth, with premature neonates displaying a slower maturation than term neonates.28 Creatinine is a degradation product of creatine which is produced by the muscles at a near constant speed and subsequently filtered passively by the kidneys into the urine. Consequently, under normal circumstances, it is a good biomarker for renal clearance, however studies show that birth creatinine reflects maternal creatinine values to subsequently peak in the first 48 hours of life irrespective of the presence of acute kidney injury related to asphyxia.12-30 Therefore, serum creatinine might not be a good indicator of renal clearance for neonates in the first days after birth.31-32 In total, 13 out of 36 studies demonstrated a significant decrease in total clearance as high as 46% during TH (table 2a-f).

Phenobarbital
Neonatal seizures in the context of HIE are treated in first line with phenobarbital, an antiepileptic drug that in adults has been replaced by other antiepileptic agents with fewer adverse effects. Phenobarbital is metabolised in the liver mostly by CYP2C9 to inactive metabolites, which are then renally excreted together with 25% of unchanged phenobarbital.33 None of the included studies measured the serum levels of phenobarbital metabolites so no final conclusions can be drawn about metabolism.34-39 About 66% of neonates with HIE and seizures respond to phenobarbital.34-35 Pokorná et al.36 observed decreased clearance during TH, although these changes were not statistically significant (table 2b). Similarly, none of the other included studies were able to detect a substantial effect of TH on the PK parameters measured.34 35 37-39 The therapeutic window for phenobarbital is 20-40 mg/L, which can be attained with an LD of 20 mg/kg that can be increased up to a maximum of 40 mg/kg if seizure control is not attained.35 38 However, a more recent study suggests to start at a higher dose of 30 mg/kg.34 Some of the authors also continued with an MD ranging from 1.5 to 8 mg/kg after the LD depending on the study.36 38 Other factors that were investigated for an effect on PK parameters were the severity of HIE and the influence of other drug.36 The severity was found to have an effect on phenobarbital clearance, likely because of a decreased cardiac output which leads to less blood flow to the kidneys and liver and a reduction in metabolic capacity. This suggests that disease severity is a more prominent covariate of phenobarbital clearance compared with TH.36 Furthermore, concomitant dobutamine administration also had an effect on phenobarbital clearance (although the authors suspect this was an artefact of the small sample size39).

Midazolam
A model compound of a drug metabolised by a CYP450 enzyme is midazolam, converted by CYP3A to 1-hydroxymidazolam and successively to 1-hydroxymidazolam glucuronide (HMG), both of which are sedative and further excreted by renal route. Midazolam is used as an add-on antiepileptic drug when seizure control with phenobarbital monotherapy is inadequate and provides an additional 23% of patients with seizure control. Intriguingly, none of the studies on midazolam showed an effect of TH on midazolam clearance.34 40 41 However, Favié et al reported on a significant reduction of the clearance of HMG (8.6% /°C), likely reflecting the impact of renal impairment34-40 41 (table 2c). Midazolam is usually concomitantly used with phenobarbital, which is an inducer of CYP3A. This effect has been quantified, so that midazolam metabolic clearance is increased by 2.33-fold during comedication with phenobarbital.34 Thus, if another antiepileptic drug is used as a first-line agent instead of phenobarbital, the dose of midazolam should be reduced by about 50%.34 A point of attention is the occurrence of hypotension during treatment with midazolam as blood pressure and plasma concentrations of midazolam have a direct relationship, with blood pressure dropping by 3.6 mm Hg for every increase in plasma concentration of 0.1 mg/L.41

Lidocaine
If there is still no seizure control after adding midazolam, lidocaine can be added as a third-line treatment, which is effective in 91% of the patients where seizure control
could not be achieved with phenobarbital and midazolam alone.\textsuperscript{22} Lidocaine is a drug frequently used as a local anaesthetic or antiarrhythmic agent and is predominantly metabolised by CYP3A into the active monoethyglycinexylidide and subsequently glycinexylidide, which is an inactive metabolite. The clearance of lidocaine was shown to be decreased by 24\% (or 8.0\%/°C) during TH.\textsuperscript{22} The extent of the impact of TH on lidocaine PK has recently been confirmed (decrease 21\%, 7.26\%/°C) in a further extended cohort of patients, including 49 neonates undergoing TH (prospective validation).\textsuperscript{49}

Morphine

Morphine is metabolised in the liver into two metabolites by the enzyme UDP-glucuronosyltransferase 2B7 (UGT2B7): morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Both morphine and its less abundant metabolite M6G are analgesic and sedative, whereas M3G is inactive. Róka \textit{et al}\textsuperscript{44} concluded that the clearance of morphine and its metabolites were decreased during TH (table 2d). This conclusion was based on differences in median morphine plasma concentration (292\textgreek{g}/\text{mL} (137–767\textgreek{g}/\text{mL}) during TH to 206\textgreek{g}/\text{mL} (88–327\textgreek{g}/\text{mL}) in normothermic neonates (p=0.014)) even though the normothermic newborns on average had received a higher dose of morphine. Unfortunately, the authors were unable to report on morphine PK. It is therefore not possible to compare the results with the subsequent studies. However, it did raise the question of altered clearance under TH and inspired others. Frymoyer \textit{et al}\textsuperscript{23} compared the PK parameters observed in their prospective study during TH to the data provided by Knibbe \textit{et al}\textsuperscript{25} during normothermia. They concluded that morphine clearance was decreased by 46.7\% (15.6\%/°C) in newborns treated with TH.\textsuperscript{23} An interesting finding in this study was that M6G accumulation is dependent on the serum creatinine. Monte Carlo simulations suggested that an LD of 50\mu g/kg followed by an MD of 5\mu g/kg or intermittent dosing of 40–50\mu g/kg every 6 hours is recommended to stay within the therapeutic window.\textsuperscript{23} The results of these simulations were seconded by the findings of two open-label prospective studies conducted in the Netherlands reported by Favić \textit{et al}.

Erythropoietin, darbepoetin and 2-iminobiotin

As second-line interventions in addition to TH, certain drugs have also been investigated for their neuroprotective effect.\textsuperscript{55–57} Erythropoietin (EPO), most well known for its haematopoietic effect, is produced by the kidneys and the brain cells (astrocytes, neurons, oligodendrocytes). EPO binds to the EPO receptor which is expressed by these same cells as well as by microglial and endothelial cells. It is proposed to have an anti-inflammatory effect in addition to inhibition of cell death and promotion of angiogenesis and development of new neurons and oligodendrocytes.\textsuperscript{58–61} Combining EPO with TH is therefore hypothesised to have an additive neuroprotective effect.\textsuperscript{55–61} The synthetic darbepoetin mimics the effects of EPO, but has a longer $t_{1/2}$, enabling the use of a longer dosing interval (table 2f). Only a very small amount (<5\%) of EPO, and thus darbepoetin, is excreted first to study the effect of TH on gentamicin PK (table 2e). They compared trough concentrations between normothermic and hypothermic group, which were not significantly different, but were, with a dose of 4–5\mg/kg every 24 hours, above 2\mg/L in 36\%–44\% of neonates. They did however not calculate or measure other PK parameters but set the scene for better PK studies.\textsuperscript{46} Two retrospective studies observed a decrease by 25.0\%–35.3\% (or 8.3\%–11.7\%/°C) in the $t_1$ in neonates undergoing TH, and a significant increase in $t_{1/2}$.\textsuperscript{47,48} Another study found an increase of 29\% in clearance on postnatal age day 5, which can be considered as steady-state normothermia after rewarming.\textsuperscript{49}

With regard to gentamicin dosing, many different schemes have been explored with an increasing interval between doses, ranging from 2.5\mg/kg every 12 hours\textsuperscript{47} to $4\mg/kg$ every 24 hours\textsuperscript{48} to 4–5\mg/kg every 36 hours.\textsuperscript{48,51} Just increasing the dosing interval from 24 to 36 hours reduced the number of newborns with trough concentrations under 2\mg/L from 62\% to 96\% without compromising on the percentage reaching the peak concentration.\textsuperscript{51} But whatever dosing regimen is used, all studies recommend therapeutic drug monitoring (TDM), and the same holds true for other aminoglycosides (like amikacin).\textsuperscript{49}

Apart from gentamicin, other antibiotics have also been investigated: ampicillin, amoxicillin, amikacin and benzylpenicillin.\textsuperscript{24,52–54} The PharmaCool study group observed a 55\%–56\% increase in clearance of amoxicillin and benzylpenicillin after postnatal age day 5, which can be considered as reaching normothermic steady state.\textsuperscript{52,54} Based on subsequent simulations, the authors suggest implementing a GA-dependent dosing regimen, with a lower dose for GA of 36–37 weeks. Both Gies \textit{et al}\textsuperscript{51} and Cristea \textit{et al}\textsuperscript{54} also quantified the decrease in clearance (by 69.3\% and 40.6\% respectively) during TH, leading for the latter in an extension in dosing interval to 42 hours instead of 30 hours. The percentage of neonates reaching toxic trough concentrations is thereby reduced from 40\%–76\% to 14\%–17\%.\textsuperscript{54}

Antibiotics

Gentamicin is an aminoglycoside antibiotic administered empirically to most neonates with HIE and is predominantly eliminated renally. Ideally the dose should generate a peak concentration of 10–12\mg/L and a trough concentration not exceeding 2\mg/L, as this could cause ototoxicity and nephrotoxicity. Liu \textit{et al}\textsuperscript{66} were the
unchanged by the kidneys. The majority is degraded in the body, possibly by intracellular degradation, of which the exact mechanisms are for the main part unknown.

Wu et al performed a phase I prospective study to determine the optimal dosing of EPO in humans by testing different doses ranging from 250 to 2500 U/kg per dose every 48 hours. This article shows that with an increase in dose, clearance decreased from 15.6±6.3 to 7.7±0.9 mL/kg/hour. The dose of 1000 IU/kg had the best AUC and C_max for the administered dose.

They also concluded that neonates with HIE which is considerably lower than a study reported for an increase in dose, clearance decreased from 15.6±6.3 to 7.7±0.9 mL/kg/hour. This article shows that with an increase in dose, clearance decreased from 15.6±6.3 to 7.7±0.9 mL/kg/hour. The dose of 1000 IU/kg had the best AUC and C_max for the administered dose (similar to those of a study with rats). A third placebo control group was needed to determine the optimal dosing of EPO in humans by including both the phase I trial mentioned above and the subsequent phase II study, found a C_L of 8.3 mL/kg/hour which is considerably lower than a study reported for premature extremely low birthweight neonates (13.1 mL/kg/hour). They also concluded that neonates with HIE receiving TH will typically have a 50% higher exposure after the same EPO dose. The recommended dose used was 1000 IU/kg every 24 hours for three doses and then two doses every 48 hours. The phase II trial found a clinical benefit of administering the EPO with significantly better brain MRI and motor function at 12 months. The corresponding phase III is momentarily still in progress.

Baserga et al administered two doses of the EPO-derived molecule Darbe (darbepoetin), one on day 0 and one on day 7. They divided the neonates into two treatment groups with one group receiving 2 µg/kg while the other was administered a higher dose of 10 µg/kg. A third placebo control group was needed to determine the baseline EPO as the quantification machines cannot distinguish between endogenously produced EPO and the synthetic Darbe. The group receiving the higher dose had an AUC that best matched that of animal studies. Roberts et al also concluded that GA is inversely correlated with C_L, meaning that preterm neonates have a higher clearance than term neonates.

2-Iminobiotin is another potential neuroprotective agent. A dose seeking (to target exposure) study in two consecutive cohorts of six neonates undergoing TH has recently been reported, and dosing for the second cohort had to be adapted to further compensate for the renal impairment associated with asphyxia. The median clearance in these 12 cases was 0.38 L/hour, but cannot be compared with data in non-cooled or healthy neonates.

**DISCUSSION**

Compared with the latest structured review (2015) that provided information on the PK during TH for four compounds (gentamicin, topiramate, phenobarbital, morphine), the current systematic search provided PK data on 15 compounds, reflecting the impressive and relevant progress made in this specific field of neonatal pharmacology since 2015.

Based on the available data, it is difficult to compare PK data in HIE newborns with or without TH due to the small number of studies that include normothermic HIE controls, as TH is now standard practice in most countries. It would thus be unethical not to offer the best care (ie, TH). Therefore, the control group are often neonates who do not suffer from HIE, which in turn makes it difficult to disentangle the effect of HIE from TH.

Phenobarbital is a relatively old antiepileptic drug, which in adults has been substituted by newer agents. However, it remains one of the most effective antiepileptic drugs for neonatal seizures. Pending the outcome of ongoing comparative studies on the use of phenobarbital or levetiracetam as first-line antiepileptic, it is possible that levetiracetam or another antiepileptic drug will replace phenobarbital. However, as phenobarbital has an inducing effect on the metabolism of midazolam (which is often coadministered), if phenobarbital were to be replaced by levetiracetam, the dosage of midazolam needs to be reduced if we aim for similar exposure. Along the same line, and because levetiracetam is mainly eliminated by renal route, it is reasonable to expect a similar decrease in renal clearance as quantified for aminoglycosides (table 2e). Such an ‘informed’ approach to anticipate for the impact of renal impairment on dosing to attain a given target exposure has been described in the 2-aminobiotin paper.

This article only explored the impact of HIE+TH on the PK in neonates. But in the clinical setting, pharmacodynamics, the effect that the drug has on the body, also needs to be considered. For antiepileptic drugs, this means the seizure control response documented by amplitude-integrated electroencephalography (aEEG). The only study in which this was quantified until present is van den Broek et al who found that administering phenobarbital to neonates undergoing TH reduced transition from continuous normal voltage to discontinuous normal voltage aEEG background level. The only other pharmacodynamic parameter evaluated is target attainment of antibiotics which was calculated using the fT>MIC ratio (minimal inhibitory concentration), which is the time that the free concentration of the substance is higher than the minimal inhibitory concentration. Although Cies et al administered 100 mg/kg ampicillin every 8 hours, their modelling predicted that 25 or 50 mg/kg every 24 hours would actually be sufficient to attain a target of 50% and even 100% of time above MIC. Bijleveld et al also used simulations to recommend a GA-dependent dosing regimen: 50 mg/kg/day of amoxicillin for GA of 36–37 weeks and 75 mg/kg/day for GA 38–42 in three doses for 7 days, which result in target attainment of 100% for *Streptococcus agalactiae* and *Listeria monocytogenes*. The Dutch paediatric formulary currently advises a dose of 75 mg/kg/day in three doses for all neonates who are younger than 7 days postnatal age and have birth weight of over 2 kg.

The Dutch paediatric formulary is an illustration on how published data can subsequently be assessed and provided as specific dosing regimens to facilitate knowledge diffusion and access. Because of this assessment (one of the criteria is prospective validation, a confirmation of a suggested dosing regimen), not all published
data are immediately present in this formulary (table 3). Furthermore, TDM can be used to verify if a given drug exposure is within the therapeutic range. This mainly relates to drugs where TDM is routinely performed like phenobarbital or aminoglycosides (gentamicin, amikacin), but may be considered also for midazolam and its metabolite (prolonged sedation related to metabolite accumulation), lidocaine (cardiac effects) or topiramate (therapeutic failure if used as antiepileptic, also relevant for phenobarbital, midazolam, lidocaine).12 75

CONCLUSION

The aim of this paper was to determine the effect of lowering the core body temperature of the neonate with HIE, on the PK of different drugs used during TH. This was evaluated by comparing values for the different PK processes: absorption, distribution, metabolisation and elimination. Depending on drug and elimination route, TH has clinical relevant effects on PK.

Correction notice This article has been corrected since it was first published. Provenance and peer review statement has been Corrected.

Contributors ICL was responsible for the study design, conducted the literature search and was responsible for the writing process of the manuscript. She finalised the final version and approved the final draft. KA assisted in the writing process of the paper, supervised the final version and approved the final draft. He is the corresponding author to the paper. JNAd was responsible for the study design, assisted in the writing process of the paper and approved the final draft. HM was responsible for the study design, assisted in the literature search and the writing process of the paper, supervised the final version and approved the final draft.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests This paper is an adapted version of the master’s thesis written by ICL.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer-reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. All data relevant to the study are included in the article or uploaded as supplementary information. All data as retrieved have been provided in the document, with structured references in table 2a–f, and the information on the corresponding author has been provided.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Karel Allegaert http://orcid.org/0000-0001-9921-5105
Jan N de Hoon http://orcid.org/0000-0002-5215-9836

REFERENCES

1 Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev 2010;86:329–38.
2 Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013;CD003311.
3 Leviton A, asphyxia P. Perinatal asphyxia.. Pediatr Neurol 1987:3:123.
4 Executive summary: neonatal encephalopathy and neurologic outcome, second edition. Report of the American College of Obstetricians and Gynecologists’ Task force on neonatal encephalopathy. Obstet Gynecol 2014;123:896–901.
5 Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976;33:696–705.
6 Thompson CM, Puterman AS, Linley LL, et al. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr 1997;86:757–61.
7 Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 2005;365:663–70.
8 Azzopardi D, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2010;364:132–3.
9 Shankaran S, Laptook AR, Tyson JE, et al. Evolution of neonatal encephalopathy during whole body hypothermia for neonatal hypoxic-ischemic encephalopathy. J Pediatr 2012;160:567–72.
10 Jacobs SE, Morley CJ, Inder TE, et al. Whole-Body Hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. Arch Pediatr Adolesc Med 2011;165:692–700.
11 Nair J, Kumar VHS. Current and emerging therapies in the management of hypoxic ischemic encephalopathy in neonates. Children 2018;5:99.
12 Smits A, Annaert P, Van Cruchten S, et al. A physiology-based pharmacokinetic framework to support drug development and dose precision during therapeutic hypothermia in neonates. Front Pharmacol 2020;11:587.
13 Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002;96:1336–45.
14 Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009;50:2365–61.
15 Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D 2016;16:303–16.
16 Nuñez-Ramiro A, Benavente-Fernández I, Valverde E, et al. Topiramate plus cooling for hypoxic-ischemic encephalopathy: a randomized, controlled, multicenter, double-blinded trial. Neonatology 2019;116:76–84.
17 Marques M, Garcia-Robles A, Usach I, et al. Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimized dosing schedule. Acta Paediatr 2019;1–9.
18 Robertson NJ, Martinello K, Lingam I, et al. Melatonin as an adjunct to therapeutic hypothermia in the neonatal encephalopathy: a translational study. Neurobiol Dis 2019;121:240–51.
19 Robertson NJ, Faulkner S, Fleiss B, et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013;136:90–106.
20 Carloni S, Facchinetti F, Pelizzi N, et al. Melatonin acts in synergy with hypothermia to reduce oxygen-glucose deprivation-induced cell death in rat hippocampus organotypic slice cultures. Neonatology 2018;114:364–71.
21 Baldini W, Weiss MD, Carloni S, et al. Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. J Pineal Res 2019;66:1–11.
22 Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth 2014;24:30–8.
23 Frymoyer A, Bonifacio SL, Drover DR, et al. Decreased morphine clearance in neonates with hypoxic ischaemic encephalopathy receiving hypothermia. J Clin Pharmacol 2017;57:64–76.
24 Cies JJ, Fugarolos KN, Moore WS, et al. Population pharmacokinetics and pharmacodynamic target attainment of ampicillin in neonates with Hypoxic-Ischemic encephalopathy in the setting of controlled hypothermia. Pharmacotherapy 2017;37:456–63.
25 Knibbe CAJ, Krekelis EHJ, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009;48:371–85.
26 Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother 2014;58:3013–20.
27 Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007;35:2196–204.
Bijleveld YA, de Haan TR, van der Lee JH, et al. Evaluation of a system-specific function to describe the pharmacokinetics of benzylpenicillin in term neonates undergoing moderate hypothermia. *Antimicrob Agents Chemother* 2018;62:1–13.

51. Favié LMA, Peeters ET, van den Brakel W, et al. Population pharmacokinetics of amoxicillin in term neonates undergoing moderate hypothermia. *Clin Pharmacol Ther* 2018;103:458–67.

52. Cristea S, Smits A, Kula O, et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. *Antimicrob Agents Chemother* 2017;61:1–9.

53. Krumal A, Uysal N, Tuyan K, et al. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. *Behav Brain Res* 2004;153:77–86.

54. Elmahdy H, El-Mashad A-R, El-Bahrawy H, et al. Human recombinant erythropoetin in asphyxia neonatorum: pilot trial. *Pediatrics* 2010;125:1135–42.

55. Zhu C, Kang W, Xu F, et al. Erythropoetin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. *Pediatrics* 2009;124:e218–26.

56. Rangarajan V, Juul SE. Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection. *Pediatr Neurol* 2014;45:141–8.

57. Bel F, Groenendaal F. Drugs for neuroprotection after birth asphyxia: pharmacologic adjuncts to hypothermia. *Semin Perinatol* 2016;40:152–9.

58. Gonzalez FF, Larpthaveesarp A, McQuillen P, et al. Erythropoietin increases neurogenesis and oligodendrocytes of the subventricular zone precursor cells after neonatal stroke. *Stroke* 2013;44:753–8.

59. Jantzie LL, Miller RH, Robinson S. Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury. *Pediatr Res* 2013;74:658–67.

60. Wu YW, Mathur AM, Chang T, et al. High-Dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. *Pediatrics* 2016;137:e20160191.

61. Rogers EE, Bonifacio SL, Glass HC, et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. *Pediatr Neurol* 2014;51:657–62.

62. Malla RR, Asimi R, Tel MA, et al. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. *J Perinatol* 2017;37:596–601.

63. Garg B, Sharma D, Bansal A. Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic-ischemic encephalopathy; presently where do we stand. *J Matern Fetal Neonatal Med* 2018;31:3214–24.

64. Flaharty KK, Car J, Erslev A, et al. Pharmacokinetics and erythropoietin response to human recombinant erythropoietin in healthy men. *Clin Pharmacol Ther* 1990;47:557–64.

65. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NEPS). *J Biol Chem* 2006;281:20241–32.

66. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. *Pediatrics* 2012;130:683–91.

67. Statler PA, McPherson RJ, Bauer LA, et al. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. *Pediatr Res* 2007;61:671–5.

68. Frymoyer A, Juul SE, Massaro AN, et al. High-Dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. *Pediatr Res* 2017;81:865–72.

69. Juul SE, McPherson RJ, Bauer LA, et al. A phase II/I trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. *Pediatrics* 2006;118:2391–4.

70. Baserga MC, Beachy JC, Roberts JK, et al. Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. *Pediatr Res* 2015;78:315–22.

71. Roberts JK, Stockmann C, Ward RM, et al. Population pharmacokinetics of darbepoetin alfa in conjunction with hypothermia for the treatment of neonatal hypoxic-ischemic encephalopathy. *Clin Pharmacokinet* 2015;54:1237–44.

72. Favié LMA, Peeters-Schofte CMPDC, Bakker A, et al. Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminothiolin in asphyxiated neonates treated with therapeutic hypothermia. *Pediatr Res* 2014;75:1126–32.

73. Pokorna P, Wildschut ED, Vobrusa V, et al. The impact of hypothermia on the pharmacokinetics of drugs used in neonates and young infants. *Curr Pharm Des* 2015;21:5705–24.

74. Favrais G, Ursino M, Mouchel C, et al. Levetiracetam optimal dose finding as first-line seizure treatment for neonates suffering in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. *BMJ Open* 2019;9:e022739.
77 Cies JJ, Habib T, Bains V, et al. Population pharmacokinetics of gentamicin in neonates with Hypoxic-Ischemic encephalopathy receiving controlled hypothermia. Pharmacotherapy 2018;38:1120–9.
78 Martinková J, Pokorná P, Záhora J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010;32:2400–14.
79 Kinderformularium.nl. Geneesmiddel | Amoxicilline | Kinderformularium, 2020. Available: https://kinderformularium.nl/geneesmiddel/7/amoxicilline [Accessed 11 Jan 2020].
80 van der Zanden TM, de Wildt SN, Liem Y, et al. Developing a paediatric drug formulary for the Netherlands. Arch Dis Child 2017;102:357–61.
81 Jullien V, Pressler RM, Boylan G, et al. Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. J Clin Pharmacol 2016;56:284–90.
82 Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol 2015;14:469–77.